Fig. 2From: Clinical features as potential prognostic factors in patients treated with nivolumab for highly pretreated metastatic gastric cancer: a multicenter retrospective studyPatients who were able to receive therapy subsequent to nivolumab showed significantly better overall survival than those who were not (p < 0.0001)Back to article page